Literature DB >> 20655339

Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart.

Bhawanjit K Brar1, Erik Helgeland, Sushil K Mahata, Kuixing Zhang, Daniel T O'Connor, Karen B Helle, Anne K Jonassen.   

Abstract

In acute myocardial infarction increased plasma levels of chromogranin A are correlated with decreased survival. At the human chromogranin A gene locus there are two naturally occurring amino acid substitution variants within the catestatin region, i.e. Gly³⁶⁴Ser and Pro³⁷⁰Leu, displaying differential potencies towards inhibition of nicotinic cholinergic agonist-evoked catecholamine secretion from sympathochromaffin cells and different degrees of processing from the prohormone. Here, we examine whether two of the variants and the wild type catestatin may affect the development of infarct size during ischemic reperfusion in the Langendorff rat heart model. The hearts were subjected to regional ischemia followed by reperfusion in the presence or absence of synthetic variants of human catestatin. Compared to the Gly³⁶⁴Ser variant both the wild type and Pro³⁷⁰Leu variants increased infarct size while decreasing the cardiac levels of phosphorylated Akt and two of its downstream targets, FoxO1 and BAD. In conclusion, these findings suggest that, in contrast to the Gly³⁶⁴Ser variant, wild type catestatin and the Pro³⁷⁰Leu variant (allele frequency ~0.3%) increased myocardial infarct size via a mechanism involving dephosphorylation of Akt and the two downstream targets during ischemic reperfusion in the isolated rat heart.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655339      PMCID: PMC2998543          DOI: 10.1016/j.regpep.2010.07.153

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  57 in total

1.  Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.

Authors:  Nilima Biswas; Sucheta M Vaingankar; Manjula Mahata; Madhusudan Das; Jiaur R Gayen; Laurent Taupenot; Justin W Torpey; Daniel T O'Connor; Sushil K Mahata
Journal:  Endocrinology       Date:  2007-11-08       Impact factor: 4.736

2.  B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart.

Authors:  Dwaine S Burley; Gary F Baxter
Journal:  Basic Res Cardiol       Date:  2007-09-26       Impact factor: 17.165

3.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

4.  Chromogranin B regulates calcium signaling, nuclear factor kappaB activity, and brain natriuretic peptide production in cardiomyocytes.

Authors:  Felix M Heidrich; Kun Zhang; Manuel Estrada; Yan Huang; Frank J Giordano; Barbara E Ehrlich
Journal:  Circ Res       Date:  2008-04-17       Impact factor: 17.367

5.  Variability in secondary structure of the antimicrobial peptide Cateslytin in powder, solution, DPC micelles and at the air-water interface.

Authors:  Frantz Jean-François; Lucie Khemtémourian; Benoît Odaert; Sabine Castano; Axelle Grélard; Claude Manigand; Katell Bathany; Marie-Hélène Metz-Boutigue; Erick J Dufourc
Journal:  Eur Biophys J       Date:  2007-07-07       Impact factor: 1.733

6.  Catestatin (chromogranin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothelin signaling in the frog heart.

Authors:  Rosa Mazza; Alfonsina Gattuso; Cinzia Mannarino; Bhawanjit K Brar; Sandra Francesca Barbieri; Bruno Tota; Sushil K Mahata
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-09       Impact factor: 4.733

Review 7.  Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction.

Authors:  Antonio Rodríguez-Sinovas; Yaser Abdallah; Hans Michael Piper; David Garcia-Dorado
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

8.  Bromelain induces cardioprotection against ischemia-reperfusion injury through Akt/FOXO pathway in rat myocardium.

Authors:  Bela Juhasz; Mahesh Thirunavukkarasu; Rima Pant; Lijun Zhan; Suresh Varma Penumathsa; Eric R Secor; Sapna Srivastava; Utpal Raychaudhuri; Venugopal P Menon; Hajime Otani; Roger S Thrall; Nilanjana Maulik
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-11       Impact factor: 4.733

9.  Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism.

Authors:  Sandra Cappello; Tommaso Angelone; Bruno Tota; Pasquale Pagliaro; Claudia Penna; Raffaella Rastaldo; Angelo Corti; Gianni Losano; Maria Carmela Cerra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-04-06       Impact factor: 4.733

Review 10.  The paradigm of postconditioning to protect the heart.

Authors:  C Penna; D Mancardi; S Raimondo; S Geuna; P Pagliaro
Journal:  J Cell Mol Med       Date:  2007-12-20       Impact factor: 5.310

View more
  10 in total

Review 1.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 2.  Chromogranin A: a paradoxical player in angiogenesis and vascular biology.

Authors:  Karen B Helle; Angelo Corti
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

Review 3.  Role of Catestatin in the Cardiovascular System and Metabolic Disorders.

Authors:  Ewa Zalewska; Piotr Kmieć; Krzysztof Sworczak
Journal:  Front Cardiovasc Med       Date:  2022-05-19

4.  Catestatin reduces myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial KATP channels and ROS signalling.

Authors:  Maria-Giulia Perrelli; Francesca Tullio; Carmelina Angotti; Maria Carmela Cerra; Tommaso Angelone; Bruno Tota; Giuseppe Alloatti; Claudia Penna; Pasquale Pagliaro
Journal:  Pflugers Arch       Date:  2013-01-15       Impact factor: 3.657

5.  Functional genetic variants of the catecholamine-release-inhibitory peptide catestatin in an Indian population: allele-specific effects on metabolic traits.

Authors:  Bhavani S Sahu; Jagan M Obbineni; Giriraj Sahu; Prasanna K R Allu; Lakshmi Subramanian; Parshuram J Sonawane; Pradeep K Singh; Binu K Sasi; Sanjib Senapati; Samir K Maji; Amal K Bera; Balashankar S Gomathi; Ajit S Mullasari; Nitish R Mahapatra
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

6.  Catestatin exerts direct protective effects on rat cardiomyocytes undergoing ischemia/reperfusion by stimulating PI3K-Akt-GSK3β pathway and preserving mitochondrial membrane potential.

Authors:  Eleonora Bassino; Sara Fornero; Maria Pia Gallo; Clara Gallina; Saveria Femminò; Renzo Levi; Bruno Tota; Giuseppe Alloatti
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

7.  Correlation of plasma catestatin level and the prognosis of patients with acute myocardial infarction.

Authors:  Dan Zhu; Hong Xie; Xinyu Wang; Ying Liang; Haiyi Yu; Wei Gao
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

8.  Catestatin and vasostatin concentrations in healthy dogs.

Authors:  Thanikul Srithunyarat; Ragnvi Hagman; Odd V Höglund; Ulf Olsson; Mats Stridsberg; Supranee Jitpean; Anne-Sofie Lagerstedt; Ann Pettersson
Journal:  Acta Vet Scand       Date:  2017-01-03       Impact factor: 1.695

9.  Catestatin attenuates endoplasmic reticulum induced cell apoptosis by activation type 2 muscarinic acetylcholine receptor in cardiac ischemia/reperfusion.

Authors:  Feng Liao; Yang Zheng; Junyan Cai; Jinghui Fan; Jing Wang; Jichun Yang; Qinghua Cui; Guoheng Xu; Chaoshu Tang; Bin Geng
Journal:  Sci Rep       Date:  2015-11-16       Impact factor: 4.379

Review 10.  Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective.

Authors:  Josko Bozic; Marko Kumric; Tina Ticinovic Kurir; Hrvoje Urlic; Dinko Martinovic; Marino Vilovic; Nada Tomasovic Mrcela; Josip A Borovac
Journal:  Biomedicines       Date:  2021-11-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.